BIAF vs MLEC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.
MLEC exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across nearly all health metrics. The company is currently pre-revenue with 0.00% margins and a catastrophic price trajectory, losing 93% of its value over the last year and 99.5% over five years. With no Graham Number or Intrinsic Value calculable due to the lack of earnings and revenue, the stock is trading as a highly speculative micro-cap with deteriorating momentum.
Compare Another Pair
Related Comparisons
BIAF vs MLEC: Head-to-Head Comparison
This page compares bioAffinity Technologies, Inc. (BIAF) and Moolec Science SA (MLEC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.